Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Advance Auto Parts

Broadcom

Cigna

Carlisle Companies

Coterra Energy

Deere & Company

EOG Resources

Invitation Homes

Lennar

Lowe's

Pool

T. Rowe Price Group

Taiwan Semiconductor Manufacturing

This article will focus on DGI stocks that are likely to provide a high rate of dividend growth rather than a high current yield. High-growth dividend stocks are particularly suited for folks who are in the accumulation phase and are several years away from retirement.

Top 10 Dividend Growth Stocks For January 2023

In this article, I'm initiating coverage of Zoetis, the world's leading animal healthcare company. While the stock has a low yield of less than 1%, the company has terrific financials, fast growth, high dividend growth, and stock buybacks boosting earnings per share.

Zoetis Is An Awesome Dividend Growth Stock

Sluggish growth and multiple headwinds weighed on the stock.

Why Zoetis Stock Lost 40% in 2022

Collegium Pharmaceutical

COLL vs. ZTS: Which Stock Is the Better Value Option?

Amazon

Take-Two Interactive Software

Analysts think these stocks can rise by 40% or more from their current levels.

These 3 Stocks Crashed by 40% in 2022. But Analysts Remain Bullish On Them

Zoetis has a very strong competitive moat resulting from its patents, scale, and respected brands. It has been delivering above-market growth for many years, and its profit margins have been on an upward trend.

It's A Great Time To Buy Zoetis Shares

Citigroup

Darling Ingredients

Kraft Heinz

Coca-Cola

Pfizer

United Rentals

Investors are entering a new era that could very well be dominated by value investing for quite some time. As a result, investors should look for undervalued value stocks to buy now.

The 7 Most Undervalued Value Stocks to Buy Now

Zoetis' business is generally stable and very consistent -- but the same can't be said for its struggling stock.

Is Zoetis Stock a Buy?

Aehr Test Systems

Applied Materials

Bank of America

Clean Harbors

Cooper Companies

Federal Signal

Illumina

Lam Research

Mastercard

Micron Technology

Parsons Corp

Charles Schwab

Smith-Midland Corporation

Stock picking is an art in a tough market. Learn which companies mutual fund managers believe can grow during economic uncertainty.

Mutual Funds Are Investing In 'Survivors' For 2023

Tesla

Accenture Plc

Arista Networks

Carrier Global

Charter Communications

Dow Inc

Estee Lauder

Edwards Lifesciences

Fidelity National Information

Fortinet

Hilton Worldwide Holdings

IQVIA Hlds

Moderna

ServiceNow

Otis Worldwide

PayPal

In the worst year for stocks since the Great Recession, several big names are headed for their worst year on record with just one trading day left in 2022.

Tesla is not alone: 18 (and a half) other big stocks are headed for their worst year on record

HEICO

Hingham Institution for Savings

Netflix

Roper Technologies

Visa

2022 wasn't a banner year for most investors. Major American equity markets fell into bear market territory.

7 Long-Term Stocks to Put on Your Buy List in 2023

Assertio Therapeutics Inc

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Teladoc

These companies' recent stock market performances don't tell the whole story.

2 Beaten-Down Industry-Leading Stocks to Buy and Hold

PARSIPPANY, N.J.--( BUSINESS WIRE )--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 14, 2023. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2022 financial results and respond to questions from financial analysts during the call.

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2022 Financial Results

PARSIPPANY, N.J.--( BUSINESS WIRE )--Zoetis Inc. (NYSE:ZTS) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 1:30 p.m. PT.

Zoetis to Participate in the 41st Annual J.P. Morgan Healthcare Conference

CRISPR Therapeutics

These stocks could have significant upside opportunities ahead.

3 Beaten-Down Stocks That Could Explode Higher in 2023

Adobe

CoreCard Corp

CF Industries Holdings

2022 was a year of soaring consumer prices and falling stock prices. I'm sure most investors will be happy to put it behind them, perhaps after some tax-loss harvesting.

7 Best Bargain Stocks to Buy in 2023

News for Zoetis Stock (ZTS)